IDCases
(Jan 2021)
Cytomegalovirus proctitis as a complication of COVID-19 with immunosuppressive treatments
François Maillet,
Annabelle Pourbaix,
Diane le Pluart,
Laura Sirmai,
Speranta Andreea Postolache,
Anne Couvelard,
Nadhira Houhou-Fidouh,
Lisa Males,
Laurène Deconinck,
François-Xavier Lescure
Affiliations
François Maillet
Infectious Diseases Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France; Corresponding authors.
Annabelle Pourbaix
Infectious Diseases Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France; Corresponding authors.
Diane le Pluart
Infectious Diseases Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France
Laura Sirmai
Hepatogastroenterology Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France
Speranta Andreea Postolache
Pathology Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France
Anne Couvelard
Pathology Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France
Nadhira Houhou-Fidouh
Virology Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France
Lisa Males
Radiology Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France
Laurène Deconinck
Infectious Diseases Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France; Corresponding authors.
François-Xavier Lescure
Infectious Diseases Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France
Journal volume & issue
Vol. 24
Abstract
Read online
We report a case of reactivated biopsy-proven cytomegalovirus proctitis complicating the course of severe COVID-19 pneumonia treated with dexamethasone, anakinra and lopinavir/ritonavir. No other contributing factor was found than iatrogenic immunosuppression and COVID-19 immune dysregulation. We draw attention to the immunosuppressive risk when treating severe COVID-19 pneumonia with immunomodulators.
Keywords
WeChat QR code
Close
